Financial Performance - Total revenue for the first half of 2023 was RMB319.3 million (USD44.0 million), a decrease of 5.7% from RMB338.6 million in the first half of 2022[3]. - Gross profit decreased by 19.6% to RMB151.8 million (USD20.9 million), with a gross profit margin of 47.5%, down 8.2 percentage points from 55.7% in the first half of 2022[13]. - EBITDA for the first half of 2023 was RMB22.4 million (USD3.1 million), a decrease of 50.1% from RMB44.8 million in the first half of 2022[18]. - The company recorded a loss of RMB11.4 million (USD1.6 million) for the first half of 2023, compared to a loss of RMB3.7 million in the first half of 2022[17]. - Revenue for the six months ended June 30, 2023, was RMB319,303,000, a decrease of 5.5% compared to RMB338,594,000 for the same period in 2022[35]. - Gross profit decreased from RMB188,696,000 in 2022 to RMB151,756,000 in 2023, reflecting a decline of approximately 19.6%[35]. - Adjusted EBITDA for the six months ended June 30, 2023, was RMB26,728,000, down from RMB58,033,000 in the same period of 2022, a decrease of approximately 54%[39]. - The company reported a loss for the period of RMB11,351,000 for the six months ended June 30, 2023, compared to a loss of RMB3,746,000 in the same period of 2022[37]. - The company’s accumulated losses increased from RMB1,064,524,000 in 2022 to RMB1,150,846,000 in 2023[31]. Customer Metrics - Total active customers decreased by 6.2% year-on-year to 104,173, with new customers increasing by 46.7% to 32,685, while repeat customers decreased by 19.5% to 71,488[5]. - The number of total treatment cases decreased by 11.1% year-on-year to 256,449, with energy-based treatments declining by 14.4%[6]. - Average spending per customer increased by 6.0% from RMB1,174 in the first half of 2022 to RMB1,245 in the first half of 2023[8]. Cash and Assets - Cash and cash equivalents increased to RMB87.9 million (USD12.1 million) as of June 30, 2023, compared to RMB26.2 million as of June 30, 2022[19]. - Cash and cash equivalents increased significantly from RMB26,228,000 on June 30, 2022, to RMB87,877,000 on June 30, 2023, an increase of approximately 234%[31]. - Total assets increased from RMB569,408,000 on June 30, 2022, to RMB602,421,000 on June 30, 2023, representing an increase of approximately 5.5%[31]. - Non-current liabilities decreased from RMB223,989,000 in 2022 to RMB114,995,000 in 2023, a reduction of approximately 48.5%[33]. Strategic Initiatives - The company plans to enhance its informational and digital infrastructure to improve customer relationship management and data-driven decision-making[2]. - The renovation of Shenzhen Pengcheng Hospital was completed in July 2023, marking a significant step towards modernization in the aesthetic medical industry[21]. - The company operates through treatment centers across major cities in mainland China, focusing on the Guangdong-Hong Kong-Macau Greater Bay area and the Yangtze River Delta area[27]. Shareholder Actions - The company closed a share transfer of 21,321,962 ordinary shares and issued 12,088,808 ordinary shares at a conversion price of RMB4.203 per share[23].

Aesthetic Medical International Holdings Group Limited (NASDAQ:AIH) Q1 2023 Earnings Conference Call May 17, 2023 8:00 AM ET Company Participants Derrick Shi - IR Associate Director Toby Wu - CFO Conference Call Participants Operator Good morning, ladies and gentlemen. Thank you for standing by, and welcome to the Aesthetic Medical International First Quarter 2023 Earnings Conference Call. During today's presentation, all parties will be in a listen-only mode. As a reminder, today's conference call is being ...

Aesthetic Medical International Holdings Group Limited (NASDAQ:AIH) Q4 2022 Earnings Conference Call April 21, 2023 8:00 AM ET Company Participants Pengwu Zhou - Chairman & Chief Executive Officer Toby Wu - Chief Financial Officer Derrick Shi - Investor Relations Associate Director Conference Call Participants Operator Good morning, ladies and gentlemen. Thank you for standing by, and welcome to Aesthetic Medical International Fiscal Year 2022 Earnings Conference Call. During today's presentation, all parti ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANG ...

Financial Data and Key Metrics Changes - Total revenue for Q3 2022 decreased by 0.3% year-on-year to RMB 167 million, primarily due to the divestment of underperforming assets and temporary closures of treatment centers due to COVID-19 [9][11] - Gross profit increased by 22.5% year-on-year to RMB 86.6 million, with gross profit margin rising by 9.6 percentage points from 41.8% to 51.8% [9][10] - The company recorded a loss of RMB 52.4 million in Q3 2022, compared to a loss of RMB 30.3 million in Q3 2021 [11] - Adjusted EBITDA for Q3 2022 was RMB 10.6 million, rebounding from a loss of RMB 30 million in Q3 2021 [12] Business Line Data and Key Metrics Changes - The number of treatment cases increased by 4.7% year-on-year, with a 37% increase in retained treatment centers [13] - Average spending per customer rose by 15.2% from RMB 2,529 in Q3 2021 to RMB 2,915 in Q3 2022, driven by high-end bio-stimulating fillers [14] Market Data and Key Metrics Changes - The total active customers decreased by 13.5% year-on-year due to temporary business suspensions [12] - The percentage of non-surgical aesthetic medical treatments increased by 5.8 percentage points of total aesthetic treatments [13] Company Strategy and Development Direction - The company is focusing on enhancing operating efficiency through adjusted marketing strategies and streamlining operations, including collaborations with key opinion leaders and live streaming e-commerce [5][6] - The company is committed to becoming a reliable non-surgical aesthetic medical service provider and is divesting non-performing centers to improve brand equity and profitability [8] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the uncertainties from the COVID-19 pandemic but expressed confidence in the company's strategies to mitigate risks, including online marketing and prudent expansion [5][21] - The company is prepared to comply with new regulations in the aesthetic medical industry, believing it will have a smaller impact compared to competitors [22] Other Important Information - The company has engaged mystery shoppers to evaluate service quality and is renovating one of its flagship hospitals to enhance customer experience [7] Q&A Session Summary Question: Reasons for the decrease in customer numbers and strategies for acquisition and retention - Management noted that the decrease was due to investments in agencies and a focus on training employees rather than advertising. Strategies include SOP training and renovations to improve customer experience [15][16] Question: Measures to alleviate risks from COVID-19 - Management stated they are coordinating with government measures, implementing health checks, and utilizing online consultations to mitigate risks [20][21] Question: Views on new regulations in the aesthetic medical industry - Management expressed confidence in their compliance and operational strategies, believing they will be less affected than competitors [22] Question: Reasons for divesting centers in Shenzhen - The decision was based on frequent lockdowns affecting cash flow and the inability to waive rent, with no further disposal plans currently [23][24] Question: Current number of clinics and hospitals - The company currently operates 10 clinics and hospitals [24]

Aesthetic Medical International Holdings Group Limited (NASDAQ:AIH) Q2 2022 Earnings Conference Call August 17, 2022 8:00 AM ET Company Participants Pengwu Zhou - Chairman & Chief Executive Officer Derrick Chi - Investor Relations Associate Director Toby Wu - Chief Financial Officer Conference Call Participants Operator Good morning, ladies and gentlemen. Thank you for standing by and welcome to Aesthetic Medical International First Half of 2022 Earnings Conference Call. During today’s presentation, all par ...

Aesthetic Medical International Holdings Group Limited (NASDAQ:AIH) Q2 2021 Results Conference Call November 16, 2021 8:00 AM ET Company Participants Dr. Pengwu Zhou - Chairman and CEO Toby Wu - CFO Conference Call Participants Operator Good morning, ladies and gentlemen. And thank you for standing by. And welcome to Aesthetic Medical International Second Quarter and First Half of 2021 Earnings Conference Call. During today’s presentation, all parties will be in a listen-only mode. As a reminder, today’s co ...

Aesthetic Medical International Holdings Group Limited (NASDAQ:AIH) Q1 2021 Earnings Conference Call June 24, 2021 8:00 AM ET Company Participants Pengwu Zhou - Chairman and CEO Toby Wu - CFO Conference Call Participants Operator Good morning ladies and gentlemen. Thanks for standing by and welcome to Aesthetic Medical International First Quarter of 2021 Earnings Conference Call. During today's presentation, all parties will be in a listen-only mode. As a reminder, today's conference call is being recorded ...